Does creatine kinase-MB (CK-MB) isoenzyme elevation following percutaneous coronary intervention with drug-eluting stents impact late clinical outcome?

Catheterization and Cardiovascular Interventions

Volumn 70, Issue 6, 2007, Pages 826-831

  Javaid, Aamir ^a   Buch, Ashesh N ^a   Steinberg, Daniel H ^a   Slottow, Tina Pinto ^a   Roy, Probal ^a   Pichard, Augusto D ^a   Satler, Lowell F ^a   Kent, Kenneth M ^a   Gevorkian, Natalie ^a   Xue, Zhenyi ^a   Suddath, William O ^a   Waksman, Ron ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATINE KINASE MB; FIBRINOGEN RECEPTOR ANTAGONIST; HIRULOG;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOGENIC SHOCK; CATHETER THROMBOSIS; CONTROLLED STUDY; DRUG ELUTING STENT; ENZYME RELEASE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; REVASCULARIZATION; STABLE ANGINA PECTORIS; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

AGED; BIOLOGICAL MARKERS; BLOOD VESSEL PROSTHESIS IMPLANTATION; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CREATINE KINASE, MB FORM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 38049011832     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21248     Document Type: Article

References (18)

1. Califf RM, Abdelmeguid AE, Kuntz RE, Popma JJ, Davidson CJ, Cohen EA, Kleiman NS, Mahaffey KW, Topol EJ, Pepine CJ, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998;31:241-251.
2. Brener SJ, Lytle BW, Schneider JP, Ellis SG, Topol EJ. Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality. J Am Coll Cardiol 2002;40:1961-1967.
3. Stone GW, Mehran R, Dangas G, Lansky AJ, Kornowski R, Leon MB. Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: A device-specific analysis of 7147 patients. Circulation 2001;104:642-647.
4. Ricciardi MJ, Wu E, Davidson CJ, Choi KM, Klocke FJ, Bonow RO, Judd RM, Kim RJ. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation 2001;103:2780-2783.
5. Mehran R, Dangas G, Mintz GS, Lansky AJ, Pichard AD, Satler LF, Kent KM, Stone GW, Leon MB. Atherosclerotic plaque burden and CK-MB enzyme elevation after coronary interventions: Intravascular ultrasound study of 2256 patients. Circulation 2000;101:604-610.
6. Thel MC, Califf RM, Tcheng JE, Sigmon KN, Lincoff AM, Topol EJ, Ellis SG. Clinical risk factors for ischemic complications after percutaneous coronary interventions: Results from the EPIC trial. The EPIC Investigators. Am Heart J 1999;137:264-273.
7. Baim DS, Cutlip DE, Sharma SK, Ho KK, Fortuna R, Schreiber TL, Feldman RL, Shani J, Senerchia C, Zhang Y, et al. Final results of the balloon vs optimal atherectomy trial (BOAT). Circulation 1998;97:322-331.
8. Harrington RA, Lincoff AM, Califf RM, Holmes DR Jr, Berdan LG, O'Hanesian MA, Keeler GP, Garratt KN, Ohman EM, Mark DB, et al. Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: Insights from the coronary angioplasty versus excisional atherectomy trial (CAVEAT). J Am Coll Cardiol 1995;25:1693-1699.
9. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 2000;101:570-580.
10. Webb JG, Carere RG, Virmani R, Baim D, Teirstein PS, Whitlow P, McQueen C, Kolodgie FD, Buller E, Dodek A, et al. Retrieval and analysis of particulate debris after saphenous vein graft intervention. J Am Coll Cardiol 1999;34:468-475.
11. Lefkovits J, Blankenship JC, Anderson KM, Stoner GL, Talley JD, Worley SJ, Weisman HF, Califf RM, Topol EJ. Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: Evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications. J Am Coll Cardiol 1996;28:849-855.
12. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 2002;105:656-662.
13. Abdelmeguid AE, Topol EJ. The myth of the myocardial 'infarctlet' during percutaneous coronary revascularization procedures. Circulation 1996;94:3369-3375.
14. Akkerhuis KM, Alexander JH, Tardiff BE, Boersma E, Harrington RA, Lincoff AM, Simoons ML. Minor myocardial damage and prognosis: Are spontaneous and percutaneous coronary intervention-related events different? Circulation 2002;105:554-556.
15. Ioannidis JP, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol 2003;42:1406-1411.
16. Kong TQ, Davidson CJ, Meyers SN, Tauke JT, Parker MA, Bonow RO. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA 1997;277:461-466.
17. Tardiff BE, Califf RM, Tcheng JE, Lincoff AM, Sigmon KN, Harrington RA, Mahaffey KW, Ohman EM, Teirstein PS, Blankenship JC, et al. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to minimize platelet aggregation and coronary thrombosis-II. J Am Coll Cardiol 1999;33:88-96.
18. Jeremias A, Baim DS, Ho KK, Chauhan M, Carrozza JP Jr, Cohen DJ, Popma JJ, Kuntz RE, Cutlip DE. Differential mortality risk of postprocedural creatine kinase-MB elevation following successful versus unsuccessful stent procedures. J Am Coll Cardiol 2004;44:1210-1214.